CTRI/2017/08/009409进行中（未招募）2 期
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of Topical Povidone-Iodine (PVP-I, 2% [W/W]) in Pediatric Subjects for the Treatment of Molluscum Contagiosum
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Males or females aged 2-18 years at screening
- •2. MC diagnosed by a general physician, dermatologist or pediatrician who refers it and treatable by a topical agent
- •3. Individuals with at least 1, but not exceeding 15 molluscum selected in designated treatment area
- •4. Individuals whose treatment area is located anywhere on the body except for the following prohibited areas which include: eye area (including eyelids), lips, mouth cavity, nasal cavity, inner ear, palms of the hands, soles of the feet or the anogenital area
- •5. Free from any systemic or dermatologic disorder that, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events
- •6. Free from atopic dermatitis in the treatment area that, in the opinion of the investigator, will potentially get inflamed or irritated during the course of treatment
- •7. Parent or guardian able to give appropriate informed consent as determined by the approving institutional review board (IRB)
- •8. Individuals who are generally in good health as determined by the investigator
- •9.Willingness and ability of parent or guardian to read, understand, and sign the IRB-approved informed consent form after the nature of the study has been fully explained and questions have been answered
- •10. Individuals who are willing to not start any new products OTC or prescription treatments and discontinue any treatment the investigator feels may interfere with the evaluation of the test products
- •11. Individuals who are willing to avoid using cosmetic products, creams, salves, or ointments to the treatment area(s)
- •12. Individuals who are willing and able to thoroughly follow the product use instructions, attend all the scheduled visits and successfully complete the study
- •13. Individuals who are willing and able to not begin any office based treatments for the duration of the study
- •14. Female subjects of childbearing age with negative pregnancy test at the enrollment time in the study
- •15. Female subjects who are not breastfeeding at the enrolment time in the study
- •16. Female subjects that do not intend to become pregnant during their participation in the study
- •Medically acceptable forms of birth control that may be used by the subject and/or his/her partner include
- •Established use of hormonal methods of contraception (oral, injected, implanted, patch or vaginal ring) Barrier methods of contraception with spermicide: condom or occlusive cap (diaphragm or cervical/Vault caps) with a spermicidal foam/gel/film/cream or suppository; Intrauterine divide or intrauterine system; Surgical sterilization (vasectomy, tubal occlusion, bilateral salpingectomy)
- •Abstinence from heterosexual intercourse; when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (calendar, ovulation, symptothermal, post ovulation methods) and withdrawal are NOT acceptable methods of contraception
排除标准
- •1. Mentally incompetent or unable or not willing to give written informed consent via parent or guardian or meet study requirements
- •2. Known history of hypersensitivity to topical PVP-I
- •3. Significant atopic dermatitis surrounding the MC lesions as judged by the Investigator
- •4. Individual lesions greater than 5 mm in diameter
- •5. Pregnant, breastfeeding or unwilling to undergo an acceptable form of contraception for the duration of the study
- •6. Molluscum lesions located on the eye area (including eyelids), lips, mouth cavity, nasal cavity, inner ear, palms of the hands, soles of the feet or the anogenital area
- •7. Have participated in an investigational trial within 30 days prior to enrollment;
- •8.Have required or will require systemic intake of immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) within 30 days prior to enrollment or during the study
- •9.Have any uncontrolled current infection;
- •10.Female subject who is pregnant, lactating planning to become pregnant, or is breastfeeding;
- •11.Have any chronic or acute medical condition that, in the opinion of the investigator, may interfere with the study results or place the subject at undue risk (such as an immunodeficiency or relevant genetic syndrome);
- •12. Have any active malignancy or are undergoing treatment for any malignancy other than non-melanoma skin cancer;
- •13. Subjects viewed by the Principal Investigator as not being able to complete the study.
研究者
相似试验
已完成
3 期
A Clinical trial intended to compare Clindamycin Phosphate & Tretinoin combination topical gel to Ziana of Medicis and both these to Placebo in patients with mild to severe acne vulgaris.CTRI/2010/091/000363Actavis MidAtlantic LLC1,225
进行中（未招募）
1 期
Study of Topical Application of a Gel Containing the Investigational Active Ingredient Patidegib versus the same Gel Without Patidegib (Placebo) for the Prevention of New Facial Skin Tumors (Basal Cell Carcinomas) in People with Gorlin Syndrome.EUCTR2018-001462-42-ITPellePharm, Inc.150
未知
2 期
A Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Trial to Assess the Safety and Efficacy of 0.3% and 1% OPA-15406 Ointments When Administered for 4 Weeks in Pediatric Patients With Atopic DermatitisAtopic DermatitisJPRN-jRCT2080223429Otsuka Pharmaceutical Co., Ltd.60
进行中（未招募）
1 期
A 1-year Study of Topical Application of a Gel Containing the Investigational Active Ingredient Patidegib versus the same Gel Without Patidegib (Placebo) for the Prevention of New Facial Skin Tumors (Basal Cell Carcinomas) in People with Gorlin SyndromeBasal Cell Nevus SyndromeMedDRA version: 20.1Level: LLTClassification code 10004151Term: Basal cell nevus syndromeSystem Organ Class: 100000004850EUCTR2018-001462-42-NLPellePharm, Inc.150
招募中
1 期
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin SyndromeGorlin SyndromeMedDRA version: 20.1Level: LLTClassification code: 10004151Term: Basal cell nevus syndrome Class: 10010331MedDRA version: 20.0Level: LLTClassification code: 10078877Term: Gorlin-Goltz syndrome Class: 10010331CTIS2023-507528-21-00Sol-Gel Technologies Ltd.156